Year-end Sale % OFF 
Abstract
The current multidisciplinary treatment for patients with high-risk neuroblastoma (NB) is the common census. However, protocols and opinions are different in different regions and institutions. We aimed to assess the protocol formulated by Chinese Children’s Cancer Group study in 2009, and the impact of surgery extent was highlightly evaluated.MethodsThis study enrolled patients with high-risk neuroblastoma between 2009 and 2014 in Department of Pediatric Oncology of Tianjin Medical University Cancer Institute and Hospital. The clinical characteristics of patients were illustrated and surgery extent was evaluated by the impact on survival rate.ResultsThe 3-year overall survival (OS) and progression-free survival (PFS) were 56.2% and 50.5%, respectively. LDH (P<0.001), bone marrow metastasis at time of diagnosis (P=0.001), bone marrow negative after neoadjuvant chemotherapy (P<0.001), radiotherapy (P<0.001) were significant predictors of OS and PFS. And surgery extent had no impact on the enhancement of high-risk neuroblastoma patients in short time.ConclusionsThis study showed no substantial survival benefit in patients with high-risk NB undergoing gross total tumor resection. Multidisciplinary intensive treatment was essential, especially for patients received subtotal tumor resection. Longer term follow-up is needed to survey complications in surviving patients who received intensive chemotherapy and radiotherapy.
Highlights
Neuroblastoma (NB) is the second most common extracranial malignant tumor of childhood that accounts for 7-10% of all pediatric malignancies but is responsible for nearly 15% of children’s cancer deaths [1,2,3]
Surgery extent had no impact on the enhancement of high-risk neuroblastoma patients in short time
This study showed no substantial survival benefit in patients with high-risk NB undergoing gross total tumor resection
Summary
Neuroblastoma (NB) is the second most common extracranial malignant tumor of childhood that accounts for 7-10% of all pediatric malignancies but is responsible for nearly 15% of children’s cancer deaths [1,2,3]. The tumor has a preference for young children; 60% of patients are younger than 2 years old and 97% occur before their first decade [4]. Systemic therapy has led to increasing improvement in treatment of children with the disease and resulted in overall survival rate of 80% or so [8, 9]. This heterogeneous tumor reflects different degrees of maturation, varying from spontaneous regression or maturity to a quite aggressive and malignant phenotype [10]. For patients with high-risk NB, despite www.impactjournals.com/oncotarget
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
